IntegraGen announces that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the
NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial” confirms the relationship between miR-31-3p expression and the efficacy of anti-EGFR treatment.

 

Click here to view press release.